Integrative multi-omics identifies MEIS3 as a diagnostic biomarker and immune modulator in hypertrophic cardiomyopathy
MEIS3 functions as a stromal-centric immunomodulator in HCM, shaping cytokine expression and immune infiltration in the diseased heart. Its expression shows diagnostic potential and may represent a novel target for immuno-modulatory strategies. These findings open new avenues for immuno-targeted interventions in HCM management.
Authors
- Jinchen He (ORCID: https://orcid.org/0009-0003-2645-5513)
- Tianqi Wu (ORCID: https://orcid.org/0000-0002-1545-3462)
- Dejun Kong (ORCID: https://orcid.org/0000-0002-6878-9293)
- Qi Wu (ORCID: https://orcid.org/0000-0003-2034-5746)
- Jinfeng Chen (ORCID: https://orcid.org/0000-0002-4690-6778)
- Zehua Zhou
- Heng Zhu (ORCID: https://orcid.org/0000-0002-8426-2889)
- Yan Liao
- Chunmei Liu (ORCID: https://orcid.org/0000-0001-9560-3709)
- Yuyuan Wang
Institutions
- China National Nuclear Corporation (CN)
- Chengdu Medical College (CN)
- Chengdu Second People's Hospital (CN)
- Science and Technology Department of Sichuan Province (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1675467
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00